MRK - Merck Projected Sales Volume

Graphic logo of Merck & Co. (MRK)

As a defensive asset, Merck & Co., Inc. (MRK) demonstrates independence from market cycles due to stable demand for vaccines. The company's future sales levels confirm this resilience, while 605.13 determines the current status of the parameter. Pipeline transparency and management's expertise in oncology strengthen the holding's position, while high margins on blockbusters, despite significant R&D expenditures, stabilize overall profitability.

Company Future Sales Volume: MSD (MRK) for 07/04/2022 - 11/13/2026

Financial and market metric breakdowns for Merck & Co. (MRK)

- stock value and consensus price forecast:
Price Chart Merck & Co., Inc.|MRK - Broker Consensus Forecast
- market capitalization statistics:
Market Capitalization Merck & Co., Inc.|MRK - Full Takeover Company Value
- book capitalization information:
Net Assets per Single Share Merck|MRK - Company Net Assets|Market Capitalization to Book Value Ratio merck.com|MRK - Company Assets
- debt and liquidity data:
Debt to Equity Merck & Co., Inc.|MRK - Long-Term Debt to Capital Coefficient|Short-Term Debt to Capital Merck Sharp & Dohme|MRK - Company Total Debt|Debt to Book Capitalization Ratio Merck & Co., Inc.|MRK - Company Long-Term Debts|Company Current Liabilities Merck|Immediate Liquidity Ratio merck.com
- company profitability and valuation multiples indicators:
MRK - Profit After Payment of Taxes|Future Profit Merck & Co., Inc.|MRK - Company Value to Net Income|Forward P/E Multiple Merck|MRK - Price/Earnings to Growth Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Merck & Co., Inc.|MRK - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months Merck|MRK - Net earnings per share for the last four quarters|Year-over-year net earnings per share growth for the last 12 months merck.com|MRK - Earnings per share increase in current year|Earnings growth forecast for next year Merck & Co., Inc.
- total revenue and sales volume data:
MRK - Company Gross Revenue|Company Projected Revenue Merck & Co., Inc.|MRK - Market Cap to Revenue Ratio|Forward P/S Multiple Merck & Co., Inc.
Fundamental company analysis:MRK Merck & Co., Inc.
Signature product of Merck & Co.

For Merck & Co., Inc. (MRK), this indicator aggregates expected cash flows from drug sales, accounting for the inelastic demand for oncology therapies and premium pricing enabled by patent protection. By analyzing projected sales volumes, investors assess capitalization potential through the lens of future revenues, confirming the business's high fundamental resilience amid market volatility.

Analysis of competing companies

Company Projected Revenue Eli Lilly and Company (LLY)|abbvie.com - Company Revenue Forecast|Projected Sales Volume AZN (AstraZeneca)|Company Sales Forecast Novartis Corporation|NVO - Company Projected Revenue|Amgen Inc (AMGN) - Company Future Sales Volume|PFE: Projected Sales Volume|Company Expected Sales Volume sanofi.com (SNY)|Company Projected Revenue Bristol Myers Squibb|GSK: Company Future Revenue|Projected Sales Volume TAK|Company Future Sales Volume Teva Pharmaceutical Industries Ltd. TEVA|Company Projected Revenue Dr. Reddy's Laboratories RDY|Projected Sales Volume viatris.com VTRS|ROIV: Company Future Sales Volume|Company Future Revenue ZLAB (Zai Lab Ltd)|Company Revenue Forecast Valeant Pharmaceuticals|COSM: Company Projected Revenue Volume